
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS

Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
The yin/yang of inflammatory status: Blood-brain barrier regulation during sleep. VER MÁS
Efficacy, Pharmacokinetics, and Toxicity Profiles of Broad Anti-SARS-CoV-2 Neutralizing Antibody. VER MÁS
Fecha de publicación: 6 de octubre de 2021 Increased survival in puppies affected by Canine Parvovirus type II using...
Phage Display Libraries for Antibody Therapeutic Discovery and Development. VER MÁS
Fecha de publicación: Septiembre 2019 A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced...
Fecha de publicación: 6 de septiembre de 2022 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2...
Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug. VER MÁS
Fecha de publicación: 8 noviembre 22 Altered neutrophil-to-lymphocyte ratio in sepsis secondary to canine parvoviral enteritis treated with and...

+52 (55) 5729 6000 Ext. 62543
Escuela Nacional de Ciencias Biológicas. Prolongación de Carpio y Plan de Ayala S/N, Del. Miguel Hidalgo, CDMX, C.P. 11340.
©2026 UDIBI